At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
RBM-007 Injectable Solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of RBM-007 in Subjects With Treatment naïve Exudative Age-related Macular Degeneration (AMD)
In Brief
A Phase 2 clinical trial evaluating RBM-007 Injectable Solution for Age Related Macular Degeneration. Completed, enrolled 5 participants across 1 site.
Detailed Summary
This study is a single-center, open label, 4-month study, designed to evaluate the safety and treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to previously untreated neovascular AMD. Up to 5 subjects will be randomized to receive study medication. Study treatment will be administered by intravitreal injections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge Related Macular Degeneration
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartJun 2021
Primary CompletionFeb 2022
Study CompletionMar 2022
TodayJul 2026
First PostedMay 20, 2021
Enrollment StartJun 15, 2021
Primary CompletionFeb 8, 2022
Study CompletionMar 4, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.1 years ago
Interventions
RBM-007 Injectable Solutiondrug
Sterile solution